A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. (Q35234443)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. (English)

1 reference

Europe PubMed Central

7 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

author name string

Thomas C Krivak

1

1 reference

Europe PubMed Central

7 August 2017

Chunqiao Tian

2

1 reference

Europe PubMed Central

7 August 2017

G Scott Rose

3

1 reference

Europe PubMed Central

7 August 2017

Deborah K Armstrong

4

1 reference

Europe PubMed Central

7 August 2017

G Larry Maxwell

5

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

12 July 2009

1 reference

Europe PubMed Central

7 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

7 August 2017

115

1 reference

Europe PubMed Central

7 August 2017

1

1 reference

Europe PubMed Central

7 August 2017

81-85

1 reference

Europe PubMed Central

7 August 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

Reactivity of a monoclonal antibody with human ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

The CA 125 tumour-associated antigen: a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

13 July 2018

CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

26 September 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

26 September 2018

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380179

26 September 2018

Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

CA125 production by the peritoneum: in-vitro and in-vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Elevation of CA 125 in patients with benign and malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.021

7 January 2021

Identifiers

10.1016/J.YGYNO.2009.06.021

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35234443&oldid=1965381774"